A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis
Status:
Completed
Trial end date:
2007-05-16
Target enrollment:
Participant gender:
Summary
This current study is planned as a dedicated pharmacodynamic (effect of drug on the body)
study to investigate the dose response in rhinitic subjects at doses where GSK256066 has been
proven to work (200mcg) or expected to (50mcg) work. This study also aims to investigate the
lower end of the predicted therapeutic range.